Author

D. Sames

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:electrophysiology· 1 Organism:mouse· 1 Organism:rat· 1

Frequent Co-Authors

J. A. Javitch· 2 shared M. Nelson· 2 shared S. Majumdar· 2 shared A. C. Kruegel· 1 shared A. Faouzi· 1 shared A. Hodges· 1 shared A. Hunkele· 1 shared A. M. Gutridge· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

J. A. Javitch

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Novel Class of Psychedelic Iboga Alkaloids Disrupts Opioid Addiction States

V. Havel, A. C. Kruegel, B. Bechand, S. McIntosh, L. Stallings, A. Hodges, M. G. Wulf, M. Nelson, A. Hunkele, M. Ansonoff, J. E. Pintar, C. Hwu, N. Abi-Gerges, S. A. Zaidi, V. Katritch, , D. Sames

This paper introduces a new class of iboga alkaloids, oxa-iboga, which show therapeutic efficacy in opioid use disorder without cardiac risks, as demonstrated in rat models.

bioRxiv · Jul 22, 2021 · PreprintPharmacology & Toxicology

A novel mitragynine analog with low efficacy mu-opioid receptor agonism displays antinociception with attenuated adverse effects

S. Chakraborty, J. F. Diberto, A. Faouzi, S. M. bernhard, A. M. Gutridge, S. Ramsey, Y. Zhou, D. Provasi, N. Nuthikattu, R. Jilakara, M. Nelson, W. B. Asher, S. O. Eans, L. L. Wilson, S. M. Chintala, , s. majumdar

The paper develops a novel mitragynine analog with reduced mu-opioid receptor efficacy and adverse effects, showing antinociception without respiratory depression or hyperlocomotion.

bioRxiv · Apr 22, 2021Pharmacology & Toxicology